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ABSTRACT 
Purpose: The aim of our study was to evaluate the relation between hereditary thrombophilic factors leading to 
coagulation disorders and retinal vein occlusion (RVO). 
Material and Methods: A total of 45 consecutive patients with RVO group and 42 healty subjects (Control group) were 
enrolled. The mean follow-up period was 15.2±5.5 months. The following investigations were performed in  both groups: 
Factor V Leiden (FVL), prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) enzyme mutations, 
antithrombin III, protein C and S activities, fibrinogen, factor VII and VIII levels, D-dimer, activated partial thromboplastin 
time and prothrombin time/INR, complete blood count, ESR and blood biochemistry. 
Results: Factor V leiden heterozygote mutation was found in four (9%) patients in RVO and one (2.4%) in Control 
groups. Homozygote FVL  mutation and PT G20210A mutation were not found in neither of the groups. In the RVO 
group, 26 patients (57.8%) had MTHFR C677T heterozygote mutation and four (8.9%) had homozygote mutation. In the 
Control group 14 (33.3%) patients had MTHFR C677T heterozygote mutation and four (9.5%) had homozygote 
mutation. There was a significant difference in MTHFR C677T genotype distribution between the 2 groups (p=0,032). 
The serum triglyceride, glucose, fibrinogen and ESR levels were significantly higher in patients compared to the controls  
Conclusion: We believe that, in addition to all related systemic and ophthalmological investigations, hematological 
screening tests to detect hypercoagulation should be  performed while investigating the etiology in patients with RVO. 
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ÖZET 
Amaç: Çalışmamızda retina ven tıkanıklıkları (RVT) ile koagülasyon bozukluklarına yol açan herediter trombofili 
faktörleri arasındaki ilişkiyi incelemeyi amaçladık. 
Materyal ve Metod: Çalışmamıza 45 hasta RVT grubu olarak, 42 sağlıklı olgu kontrol grubu olarak dahil edildi. Takip 
süresi ortalama 15.2±5.5 aydı. Her 2 grupta Faktör V Leiden (FVL), protrombin G20210A ve metilentetrahidrofolat 
redüktaz (MTHFR) enzim mutasyonu, antitrombin III, protein C ve S aktivitesi, fibrinojen, faktör VII ve VIII seviyeleri, D-
dimer, aktive parsiel tromboplastin zamanı, protrombin zamanı/INR, CBC, ESR ve tam kan biyokimyası incelemeleri 
yapıldı. 
Bulgular: RVT grubunda 4 (%9), kontrol grubunda ise 1 (%2.4) olguda FVL heterozigot mutasyonu tespit edildi. Her 2 
grupta da homozigot FVL mutasyonu ve PT G20210A mutasyonu tespit edilmedi. RVT grubunda 26 (%57.8) hastada 
heterozigot, 4 olguda (%8.9) homozigot  MTHFR C677T  mutasyonu tespit edildi. Kontrol grubunda ise 14 (%33.3) 
olguda heterozigot ve 4(%9.5) olguda ise homozigot MTHFR C677T  mutasyonu vardı. Gruplar arasında MTHFR 
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C677T mutasyonu açısından istatistiksel olarak anlamlı fark vardı (p=0,032). RVT grubunda serum trigliserid, glukoz , 
fibrinojen ve  ESR seviyeleri kontrol grubuna göre belirgin olarak yüksek bulundu. 
Sonuç: RVT olan hastaların etyolojisini araştırırken tüm ilişkili sistemik ve oftalmolojik muayenenin yanısıra 
hiperkoagülasyon  değerlendirmesi için hematolojik testlerin yapılması gerektiğini düşünmekteyiz. 
Anahtar kelimeler: Kalıtsal trombofili, Retina ven tıkanıklığı 
INTRODUCTION 
 Retinal vein occlusion (RVO) is the second 
most common type of retinal vascular disorder 
after diabetic retinal disease, and may have 
manifestations of hemorrhage, ischemia, 
neovascularization and edema in the retina1. RVO 
may be related to systemic diseases such as 
hypertension, genetic disorders and hematological 
diseases1. Thrombophilia  is an abnormality 
of blood coagulation that increases the risk 
of thrombosis. The etiology of venous thrombosis 
is multifactorial. Abnormalities of the haemostatic 
system and hematological factors may cause 
thrombophilic states resulting in systemic vascular 
thrombosis. Most important risk factors include 
factor V Leiden (resistance to activated protein C 
[APC]), prothrombin 20210A, MTHFR C677T 
gene mutations and deficiencies in antithrombin, 
protein C, and protein S 2-4.  
 The aim of this study was to assess the 
association between hereditary thrombophilic 
factors and RVO. 
MATERIAL and METHODS 
 In this prospective study, a total of 45 
consecutive patients with RVO treated between 
2001 and 2002 at Cukurova University Faculty of 
Medicine, Department of Ophthalmology formed 
the RVO group. Fourty-two healty subjects with 
normal ophthalmological examination and without 
systemic disease formed the Control group. All 
patients in both groups were informed about the 
design of the study and written informed concent 
was obtained. 
 In the RVO group, all patients underwent 
routine ophthalmological examination and fundus 
fluorescein angiography to determine the degree of 
retina perfusion. Detailed medical histories for 
systemic diseases were acquired from all patients. 
 
 Factor V Leiden (FVL), prothrombin G20210A 
and methylenetetrahydrofolate reductase (MTHFR) 
enzyme mutations, antithrombin III (AT-III), protein 
C and S activities, fibrinogen, factor VII and VIII 
levels, D-dimer, activated partial thromboplastin 
time (APTT) and prothrombin time (PT), 
International Normalization Ratio (INR), complete 
blood count, erythrocyte sedimentation rate (ESR), 
and blood biochemictry were  investigated in both 
groups. 
 Blood samples of 4 ml were obtained  for 
mutation studies at hematology laboratory. Of the 
4 ml samples, 2 ml was stored at a maximum 
temperature of +4°C for one week until DNA 
isolations were performed. DNA isolation was 
performed in complete blood using MagNa Pure 
LC DNA Isolation Kit (Roche Applied Sciences) 
and MagNa Pure LC automatic DNA RNA isolation 
device (Roche Applied Sciences). Isolated DNA 
samples were stored at -20°C until the mutation 
analyses were performed. Factor V Leiden, 
Prothrombin G20210A and MTHFR C766T 
mutations were detected using Detection Kits 
(Roche Applied Sciences) and the LightCycler 
device. 
 Statistical Analysis: The data were installed 
and analyzed using the SPSS pocket program 
version 10.0. The non-parametric Mann-Whitney U 
test was used for differences in group means or 
distributions. The Chi-square test was used for the 
differences in distributions or for relationships 
between groups and categorical factors. Risk 
factors for disease were predicted using the 
logistic regression analysis. The measure of the 
risk: odds ratio estimated relative risk was 
calculated. Relative risk (RR) <1 meant a decrease 
in risk, and RR >1 meant an increase in risk. 
Values of p<0.05 were considered statistically 
significant. 
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RESULTS 
 The RVO group included 45 eyes of 45 
patients, 18 of  eyes (40%) had central retinal vein 
occlusion and 27 eyes (60%) had branch retinal 
vein occlusion. The mean follow-up period was 
15.2±5.5 months (7-24 months).  The demographic  
 
characteristic of the RVO and Control groups  are 
shown in Table 1. Systemic medical conditions of 
patients were given in Table 2. No patient in any of 
the  groups had a known history of blood 
disorders.
Table 1. Demografic characteristics in the RVO and Control groups. 
 RVO group (n=45) Control group (n=42) 
Age 58.6 ± 9 54.3 ± 11.3 
Gender (M/F) 23 / 22 22 / 20 
Tobacco use 9 ( %20 ) 8 ( %19 ) 
Alcohol Consumption 4 ( %8.8 ) 4 ( %9.5 ) 
Table 2. Systemic diseases in the RVO group 
 Patient (n=45) 
Diabetes mellitus (type 2) 10 ( %22.2 ) 
Hypertansion 31 ( %69 ) 
Diabetes and hypertansion 3 ( %6.6 ) 
Cardic diseises 8 ( %17.8 ) 
Serum lipid level elevation 17 ( %37.8 ) 
Deep venous thrombosis 1 ( %2.2 ) 
 
 Factor V leiden heterozygote mutation was 
found in four (9%) patients in the RVO group and 
one (2.4%) in the Control group. No homozygote 
FVL mutation was found in either of the groups. 
There was no significant difference in genotype 
distribution of patients and controls (p=0.362). No 
patient had the prothrombin G20210A variant. In 
the RVO group, 26 patients (57.8%) had MTHFR 
C677T heterozygote mutation and four (8.9%) had 
homozygote mutation. In the control group 14 
(33.3%) patients had MTHFR C677T heterozygote 
mutation and four (9.5%) had homozygote 
mutation. There was a significant difference in 
genotype distribution between the 2 groups 
(p=0,032) (Table 3). Three patients (6.7%) had 
concurrent FVL and MTHFR C677T heterozygote 
mutation. APTT, PT, INR and complete blood  
 
count plasma levels were normal in all patients in 
both groups (Table 4). ESR and fibrinogen levels 
were significantly higher in the RVO group 
(p=0.013, p=0.002, respectively). There was no 
significant difference between the two groups for 
antithrombin III, protein C and S levels (Table 5). 
 The mean serum triglyceride level (mg/dL) 
was 166.8±71  (73-398) in the RVO group, and 
114.2±26.4 (73-150) in the Control group. The 
mean serum glucose level (mg/dL) was 123±57 
(35-325) in the RVO group and  93.2±9.9 (72-110) 
in the Control group.  The serum triglyceride and 
glucose levels were significantly higher in the RVO 
group (p=0.001, p=0.022, respectively). Other 
biochemical parameters included liver enzymes, 
blood urea nitrogen, creatinine, total cholesterol 
and low density lipoprotein were normal range in 
both groups . 
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Table 3. The frequencys of gene mutations in the RVO and Control groups. 
 RVO group ( n=45 ) Control group ( n=42 ) p 
 
FVL 
Normal 41 ( %91 ) 41 ( %97.6 )  
Heterozygote 4 ( %9 ) 1 ( %2.4 p=0.362= 
Homozygous - -  
 
MTHFR C677T 
Normal 15 ( %33.3 ) 24 ( %57.2 )  
Heterozygote 26 ( %57.8 ) 14 ( %33.3 ) p=0.032 
Homozygous 4 ( %8.9 ) 4 ( %9.5 )  
 
PTG20210A 
Normal 45 ( %100 ) 42 ( %100 )  
Heterozygote - -  
Homozygous - -  
Table 4. Hematologic parameters in the RVO and Control groups. 
 RVO group ( n=45 ) Control group 
( n=42 ) 
p 
Fibrinogen ( mg/Dl ) 394 ± 30.7 343.8 ± 38.3 p= 0.002 
Factor VII ( % ) 78.2 ± 25.2 84.6 ± 21 p= 0.204 
Factor VIII ( % ) 122.5 ± 73.5 127 ± 77.5 p= 0.414 
D-dimer (aeg / dL ) 0.4 ± 0.3 0.3 ± 0.1 p= 0.057 
PT ( dk ) 13.1 ± 0.5 13.7 ± 3.1 p= 0.586 
APTT ( sn ) 28.2 ± 1.9 28.5 ± 2.2 p= 0.555 
INR 1 ± 0.04 1.1 ± 0.4 p= 0.915 
ESR ( mm/h ) 20.5 ± 16 15 ± 12.5 p= 0.013 
WBC ( 10^3/µL ) 8425 ± 2145.5 7643.8 ± 1998.8 p= 0.083 
Hb ( g/dl ) 13.2 ± 1.3 13.7 ± 1 p= 0.080 
Hct ( % ) 40 ± 3.6 41 ± 3 p= 0.563 
RBC ( 10^6/µL ) 4.8 ± 0.4 4.8 ± 0.4 p= 0.0341 
Plt ( 10^3/µL ) 279 ± 59 271 ± 69.5 p= 0.543 
 
 
 
 726 
Cilt/Volume 40 Yıl/Year 2015 Hereditary Thrombophilia in Retinal Ven Occlusion 
 
Table 5. AT III, Protein C and S deficiency in the RVO and Control groups. 
 RVO group n ( % ) Control group n ( % ) p 
AT III deficiency 5 ( %11 ) 6 ( %14.2 ) p= 0.687 
Protein C deficiency 1 ( %2.2 ) 1 ( %2.4 ) p=0.266 
Protein S deficiency - 1 ( %2.4 ) p=0.418 
DISCUSSION 
 Hypertension and primary open angle 
glaucoma have been identified as major risk 
factors for retinal vein occlusion5,6. Although it has 
been shown that genetic risk factors are important 
in the development of venous thrombosis, their 
role in RVO is not clear yet 2-4 . Factor V Leiden 
mutation is a relatively common heritable 
abnormality, and the  prevalence of heterozygote 
traits  vary between 1% to 8%,  in different 
regions7,8. Salomon et al. found that there was no 
significant difference between the prevalence of 
this mutation in the patient and the control 
groups2. In present study, we found the 
prevalence of FVL heterozygote mutation as 8.9% 
in the RVO group and 2.4% in the Control group. 
The difference was not significant between the two 
groups. However, some studies reported that there 
was a positive correlation between FVL mutation 
and RVO, and this mutation was considered as a 
risk factor in patients with RVO3. Prothrombin 
G20210A mutation is another common cause of 
hereditary thrombophilia. This mutation has been 
defined as a risk factor in cases of familial venous 
thrombosis9. Similar to FVL mutation, Prothrombin 
G20210A mutation is very rare in Asian or African 
populations10. Many studies on prothrombin 
G20210A mutation and RVO were not able to 
demonstrate a significant relationship between 
mutation and RVO2,4. Salomon et al.2 found no 
significant relationship between this mutation and 
RVO. Similarly, we also could not find this mutation 
in neither of the groups. Mutation in the 
thermolabile variant of methylenetetrahydrofolate 
reductase enzyme causes a decrease of enzyme 
activity which render these individuals more prone 
to thrombotic events11,12. The prevalence of this  
 
mutation shows a significant geographic variation 
(1.4% to 29.7%)13,14. In Turkey, the prevalence of 
MTHFR heterozygote mutation has been reported 
as 37.4% to 42% in the normal population, 
whereas homozygote mutation has been reported 
as 5.8% to 6.3% 15. Salomon et al. reported the 
risk factors in patients with RVO as hypertension, 
family history of stroke and MTHFR C677T 
homozygote mutation2. Loewenstein et al. defined 
in 1999 the significant association between RVO 
and a mutation in MTHFR C677T 16. They 
enrolled 59 consecutive patients  with newly 
diagnosed RVO and reported that 26 patients 
(44%) were heterozygotes and 11 (18.6%) were 
homozygotes for MTHFR C677T mutation. They 
found that RVO may be associated with a mutation 
in MTHFR. The authors suggested screening for 
this mutation in patients with RVO and 
administration of folic acid to prevent the 
development of thrombosis and to downgrade 
retinal vascular changes in individuals with positive 
screening16 . We also found a positive correlation 
between RVO and MTHFR C677T mutation. The 
Eye Disease Case-Control Study Group concluded 
that the RVO risk increases with hypertension, 
diabetes mellitus type 2, elevated ESR (especially 
in women) and history of glaucoma; however, the 
risk decreases with physical activity, alcohol 
consumption, and exogenous estrogen 
administration in postmenopausal women5,6. In 
our study, ESR and fibrinogen level were 
significantly higher in patients with RVO compared 
to the control group; however there was no gender 
difference. Hayreh et al. found that the most 
common systemic disease associated with RVO 
was hypertension17. In our study, 69% of the 
patients with RVO had hypertension, 6.6% had 
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diabetes mellitus and hypertension, and 17.8% 
had a history of cardiovascular disease. The 
logistic regression model, revealed elevated blood 
glucose and triglyceride levels and MTHFR677C-T 
gene mutation as other important risk factors for 
RVO. Logistic regression analysis involving the 
parameters for which significant differences were 
detected an odds ratio of 2.67 for MTHFR C677T 
gene mutation (95% confidence interval 1.1-6.4), 
an odds ratio of 1.049 for serum glucose level 
(95% confidence interval 1.008-1.091) and an 
odds ratio of 1.034 for serum triglyceride level 
(95% confidence interval 1.014-1.055).  
 RVO is a multifactorial retinal vascular 
disorder that commonly leads to severe visual 
impairment. Our results favour performing 
hematological investigations for the thrombophilic 
disorders in patients with retinal vascular 
occlusion. If a hereditary defect is found, the 
patient should undergo consultation of the 
hematology department and prophylactic 
anticoagulant treatment should be administered to 
prevent other thrombotic events. This approach 
may potentially prevent a fatal disorder such as 
cerebral or cardiac infarct.   
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